Targets & Tactics: A Bispecific Master Class for the AP

This advanced-level master class is designed for advanced practitioners (APs) in hematology/oncology who seek to deepen their expertise in the rapidly evolving field of bispecific T-cell engagers (BTCEs). Through three comprehensive modules, participants will explore the mechanisms of action, therapeutic roles, and clinical applications of FDA-approved BTCEs across multiple malignancies. The program emphasizes evidence-based strategies for optimizing patient outcomes, managing adverse events, and integrating BTCE therapy into diverse practice settings.

Participants will gain practical insights into comparing BTCEs with other immunotherapeutic approaches, tailoring treatment plans based on patient-specific factors, and implementing multidisciplinary strategies for safe and effective care delivery. Special attention will be given to toxicity mitigation, patient and caregiver education, and institutional considerations such as formulary decisions and cost management.

Learning Modules & Objectives:

Module 1: Clinical Application of BTCE's
  • Discuss mechanisms of action and therapeutic roles of US Food and Drug Administration (FDA)-approved bispecific T-cell engagers (BTCEs) in hematology/oncology malignancies.
  • Evaluate clinical trial data and guideline recommendations for BTCEs in multiple myeloma, lymphoma, and small cell lung cancer.
  • Identify unique toxicities and infectious complications associated with BTCEs and their appropriate prophylactic measures.
  • Compare BTCEs to other immunotherapeutic approaches, such as chimeric antigen receptor T-cell therapy, in terms of efficacy, safety, and logistics.
Module 2: BTCE Related Adverse Events
  • Review the adverse event profiles of current bispecific T-cell engagers (BTCEs).
  • Develop best practices to mitigate adverse events associated with BTCEs.
  • Identify unique toxicities and infectious complications associated with BTCEs and their appropriate prophylactic measures.
  • Emphasize the importance of patient and caregiver education for early recognition and management of toxicities.
Module 3: Implementing Bispecific T-Cell Engagers Into Practice: Moderated Panel Discussion
  • Discuss mechanisms of action and therapeutic roles of US Food and Drug Administration (FDA)-approved bispecific T-cell engagers (BTCEs) in hematology/oncology malignancies.
  • Evaluate clinical trial data and guideline recommendations for BTCEs in multiple myeloma, lymphoma, and small cell lung cancer.
  • Apply patient-specific factors to individualize treatment plans for patients receiving BTCE therapy.
  • Compare BTCEs to other immunotherapeutic approaches, such as chimeric antigen receptor T-cell therapy, in terms of efficacy, safety, and logistics.

Whether you’re navigating complex adverse event profiles or comparing BTCEs to other immunotherapies, this course delivers the knowledge and tools you need to lead confidently in a rapidly evolving therapeutic landscape.

Course Format:

  • Mode: Web-based, on-demand modules
  • 3.5 CE hours and 3.5 pharmacology hours. Course is accredited by ANCC, AAPA, and ACPE.


Cost $95 for non-members, Free for APSHO members

Supported by an unrestricted educational grant from Johnson & Johnson. The supporter had no role in content development.

  • Targets & Tactics: A Bispecific Master Class for the AP
    Contains 3 Product(s)

    This multi-session program provides advanced practitioners with a 360-degree view of BTCE therapy, spanning mechanisms of action, clinical trial evidence, patient selection, adverse event recognition and management, and practice implementation. The series blends evidence-based learning with case studies and multidisciplinary perspectives to prepare participants for leadership in BTCE adoption across diverse practice settings. Upon completion, learners will be able to safely and effectively apply BTCEs, improve patient and caregiver education, and contribute to system-level readiness for these novel therapies. Overall Program Learning Objectives: After completing this activity, learners will be able to: · Explain the mechanisms of action and approved indications of BTCEs. · Evaluate clinical data and guidelines supporting BTCE use. · Develop individualized patient treatment plans using BTCEs. · Recognize and manage common BTCE-related toxicities. · Integrate safety protocols into outpatient workflows. · Lead institutional and multidisciplinary efforts for BTCE adoption.